Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer ...Middle East

EAST HANOVER, N.J., Sept. 19, 2021 /PRNewswire/ -- Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal...

Hence then, the article about novartis presents new kisqali data showing longest median overall survival ever reported in hr her2 advanced breast cancer was published today ( Sunday 19/09/2021 - 03:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer )

Also on site :

• Meta lines up layoffs while Microsoft offers buyouts
• Meta Prepares 8,000 Layoffs to Offset AI Infrastructure Investments .. PYMNTS.com
• 'Days of Our Lives' Star Reveals How Motherhood Has Transformed Her Character Ahead of a Shocking Return